within Pharmacolibrary.Drugs.ATC.A;

model A04AA01_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1.0,
    Cl             = 26 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 8 / 1000000,
    adminCount     = 1,
    Vd             = 0.075,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Ondansetron is a selective serotonin 5-HT3 receptor antagonist used primarily as an antiemetic to prevent nausea and vomiting caused by cancer chemotherapy, radiotherapy, and surgery. It is approved and widely used internationally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following intravenous administration in healthy adults; parameters reflect standard IV dosing.</p><h4>References</h4><ol><li><p>Sotelo, CK, et al., &amp; Zersen, KM (2022). Pharmacokinetics and anti-nausea effects of intravenous ondansetron in hospitalized dogs exhibiting clinical signs of nausea. <i>Journal of veterinary pharmacology and therapeutics</i> 45(6) 508–515. DOI:<a href=&quot;https://doi.org/10.1111/jvp.13087&quot;>10.1111/jvp.13087</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35899472/&quot;>https://pubmed.ncbi.nlm.nih.gov/35899472</a></p></li><li><p>Quimby, JM, et al., &amp; Gustafson, DL (2014). Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats. <i>Journal of veterinary pharmacology and therapeutics</i> 37(4) 348–353. DOI:<a href=&quot;https://doi.org/10.1111/jvp.12094&quot;>10.1111/jvp.12094</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24330064/&quot;>https://pubmed.ncbi.nlm.nih.gov/24330064</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A04AA01_1;
